Auto-generated from public data. Not the firm's stated position.
BaseLaunch appears to focus on early-stage biotech investments, particularly in oncology and immunotherapy therapeutics, with a typical check size up to €0.5M at the pre-seed and seed stages. Recent portfolio companies suggest concentration in targeted cancer therapeutics and immune-modulating approaches, indicating a thesis around novel mechanisms in oncology.
Generated 1 Oct 2026 from disclosed sectors, stages, and portfolio companies. Firms can update this by emailing [email protected].
Focus and check size from the firm's website. Website reachable as of Oct 2026.
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.